André Andonian

Chair of Asia Pacific and Strategic Advisor
Flagship Pioneering
​​

André Andonian is the Chair of Asia Pacific and Strategic Advisor for Flagship Pioneering. He has over three decades of experience advising companies around the globe on a broad range of strategic, operational, and organizational topics, with a longstanding presence in the APAC region.
Andonian is Senior Partner Emeritus at McKinsey & Company, where he worked for 34 years, including as Senior Partner, Chairman of Japan, and Managing Partner of Korea. He also led Client Impact & Experience across Asia and was a member of McKinsey’s leadership teams in Asia, Europe, and the United States, advising clients in the high-tech, industrial, automotive & assembly, aerospace, basic materials, biotech, and private equity sectors. He was a long-term member of McKinsey’s global board and held extensive additional senior leadership roles in support of growth, people, and overall knowledge development.  Prior to joining McKinsey, Andonian worked at Masco Corporation in the US and at IBM in Austria, Spain, and the Middle East.
Andonian also serves as an Independent Director of the Board of Analog Devices and Invaio, Chair of the Board of Cognaize in the US, NC Chair of AEM Holdings in Singapore, Chair of the Foundation for Armenian Science and Technology, and is a Special Advisor of the American Chamber of Commerce in Korea. He lectures a graduate class, “Digital Heath Technology Innovation Lab”, at the School of Medicine and Health of the Technical University of Munich (TUM), where he also co-hosts the annual “The Future of Health Summit” and is a member of the NUS Medicine International Council. 
As a Fulbright Scholar, Andonian received an MBA at the Wharton School of the University of Pennsylvania, an MA and BA in Social & Economic Sciences as well as a BSc in Engineering, all with highest distinction, from institutions in his hometown of Vienna, Austria.

Speech title & Synopsis

Pioneering company creation model and opportunities in APAC

Flagship Pioneering, the US-based biotechnology company, recently expanded its presence into the Asia-Pacific region with the aim of broadening its impact on human health and the health of our planet. This session will focus on Flagship’s unique company creation process, which has resulted in more than 100 first-in-category bioplatform companies designed to generate multiple products. One of these companies – Empress Therapeutics – is revolutionizing small molecule drug discovery, and will be a highlight of the session. The discussion will also address opportunities for collaboration with Flagship and its ecosystem of companies, with the aim of building strategic partnerships with industry, academia, investors, and healthcare systems across Asia.